Positive topline results from Vesper Bio’s Phase Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic carriers with frontotemporal degeneration (FTD) caused by mutations in the progranulin gene (GRN). Mean progranulin levels increased by more than 95% compared to baseline at the highest dose tested. As… Read More
Vesper Bio has initiated a Phase Ib/IIa Proof of Concept (POC) study of its lead candidate VES001 for frontotemporal dementia. The SORT-IN-2 study will evaluate VES001 in patients with mutations in their progranulin-coding gene (GRN), which are causal for FTD(GRN). FTD(GRN) is an early onset degenerative brain disease which is… Read More
Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60. FTD(GRN), which… Read More
With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW’s Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition. Parkinson’s is the most common movement disorder, affecting… Read More
